Enveric Biosciences, Inc. ENVB
the laws of the State of Delaware in February 1994 as Spatializer Audio Laboratories, Inc., which was a shell company immediately prior
to the completion of a "reverse merger" transaction on May 26, 2015, whereby Ameri100 Acquisition, Inc., a Delaware corporation
and newly created, wholly owned subsidiary, was merged with and into Ameri and Partners Inc. ("Ameri and Partners"), a Delaware
corporation (the "2015 Merger"). In connection with the 2015 Merger, we changed our name to AMERI Holdings, Inc.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $39.9M | $43.0M | $48.6M | $36.1M |
| Cost of revenue | — | — | — | — | — | — | $31.8M | $34.0M | $38.4M | $29.2M |
| Gross profit | — | — | — | — | — | — | $8.2M | $9.0M | $10.2M | $6.9M |
| R&D | $2.8M | $2.8M | $7.3M | $8.0M | $4.8M | $174.1K | — | — | — | $55.1K |
| SG&A | $5.8M | $6.5M | $8.9M | $11.6M | $20.5M | $5.3M | $2.3M | $10.8M | $18.5M | $9.4M |
| Total operating expenses | — | — | — | — | — | — | $14.5M | $16.1M | $21.1M | $12.3M |
| Operating income | -$8.8M | -$9.6M | -$16.4M | -$27.4M | -$64.6M | -$5.6M | -$2.3M | -$7.1M | -$10.9M | -$5.4M |
| Interest expense | $106 | $219 | $3.7K | $5.2K | $10.3K | $445.2K | $81.8K | $729.9K | $575.0K | $751.1K |
| Pre-tax income | -$8.8M | -$9.6M | -$17.3M | -$20.0M | -$56.4M | -$6.9M | -$5.2M | -$10.5M | -$11.5M | -$6.5M |
| Income tax | — | $8.9K | $28.9K | $1.5M | $7.5M | — | $388.7K | $6.3M | $2.4M | $3.7M |
| Net income | $12.1M | $9.6M | $17.5M | -$18.5M | -$49.0M | -$6.9M | -$2.4M | -$16.9M | -$9.1M | -$2.8M |
| EPS, basic | -36.24 | -228.48 | -121.29 | -13.00 | -103.69 | — | -2.83 | -20.47 | -0.75 | -0.21 |
| EPS, diluted | -36.24 | -228.48 | -121.29 | -13.00 | -2.07 | -1.19 | -0.46 | -20.47 | -0.75 | -0.21 |
| Shares, diluted (wtd. avg.) | $334.7K | $41.9K | $143.9K | $1.4M | $472.3K | $5.8M | $5.3M | $951.6K | $15.0M | $13.1M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | — | — | — | — | — | $1.6M | $43.7K | $113.7K | $4.9M | $1.4M |
| Receivables | — | — | — | — | — | — | $6.4M | $7.9M | $8.8M | $8.1M |
| Total current assets | $4.9M | $2.7M | $3.6M | $18.4M | $17.7M | $2.3M | $108.8K | $10.1M | $14.6M | $10.1M |
| Property, plant and equipment | $159.2K | $305.8K | $507.4K | $677.5K | $294.4K | — | $83.1K | $58.9K | $95.0K | $100.2K |
| Goodwill | — | — | — | — | $1.6M | — | $13.7M | $13.7M | $21.9M | $17.1M |
| Other intangibles | — | $42.2K | $210.9K | $379.7K | $548.4K | $1.8M | $0 | $5.8M | $9.5M | $8.8M |
| Total assets | $5.1M | $3.1M | $4.3M | $19.6M | $26.7M | $4.1M | $108.8K | $29.6M | $52.2M | $39.5M |
| Accounts payable | $581.0K | $521.7K | $1.2M | $463.3K | $683.4K | — | $4.7M | $4.4M | $5.3M | $5.1M |
| Short-term debt | — | — | — | — | — | — | $4.9M | $5.2M | $749.6K | $405.4K |
| Total current liabilities | $918.4K | $1.5M | $2.3M | $4.0M | $2.7M | $681.2K | $13.5M | $14.7M | $30.4M | $12.7M |
| Long-term debt | — | — | — | — | — | — | $740.3K | $0 | $1.1M | $1.5M |
| Total liabilities | — | — | — | $4.0M | $4.4M | $681.2K | $1.9M | $18.9M | $32.7M | $27.8M |
| Retained earnings | -$114.8M | -$106.1M | -$96.5M | -$79.2M | -$60.7M | -$11.8M | -$4.9M | -$34.5M | -$15.0M | -$3.8M |
| Total equity | $4.2M | $1.6M | $2.0M | $14.7M | $22.3M | $3.4M | -$1.8M | -$65.5K | $19.4M | $11.7M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8.1M | -$7.7M | -$14.1M | -$17.1M | -$11.5M | -$3.9M | -$647.9K | -$2.6M | -$2.7M | -$2.7M |
| Depreciation and amortisation | $158.7K | $168.7K | $175.2K | $159.2K | $13.3K | — | — | — | — | $1.4M |
| Stock-based compensation | $827.3K | $1.6M | $2.2M | $2.6M | $12.6M | $2.0M | $624.1K | — | $7.1M | $1.5M |
| Capital expenditure | — | — | $5.2K | $584.2K | $189.7K | — | — | — | — | — |
| Investing cash flow | — | — | $11.7K | -$584.2K | $2.2M | -$44.1K | -$284.3K | -$3.6M | -$169.9K | -$6.6M |
| Financing cash flow | $10.6M | $7.7M | -$1.3M | $18.2M | $24.9M | $5.5M | $560.0K | $2.7M | $6.4M | $8.8M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-016543.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |